globenewswire

FORM 8.5 (EPT/RI)

Annual Developer Conference Hosts Major Semiconductor Companies for Dialogue on Latest Test Technologies and Industry Trends

Munich, Germany – July 2, 2025 -- Ebenbuild, a company developing personalized, AI-enabled digital twins of lungs to support clinical decisions and digital clinical trials, today announced that it has received Euro 2.3 million funding under the European Innovation Council (EIC) Accelerator program to advance its digital twin platform technology. In addition, the EIC fund will invest up to €10 million in future equity financing rounds raised by Ebenbuild. The funding will support the market launch of Twinhale, the first in silico trial software built for pulmonary drug delivery. The investment also underpins Ebenbuild’s broader platform strategy to transform respiratory care through personalized lung simulation – from drug development to mechanical ventilation optimization in critical care.

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

LONDON, July 02, 2025 (GLOBE NEWSWIRE) -- FWF, Teil der AROBS Group (BVB: AROBS) und spezialisiert auf intelligente Prozessautomatisierung, wurde von UiPath (NYSE: PATH), einem weltweit führenden Anbieter von agentenbasierter Automatisierung, als „Agentic Automation Fast Track Partner” ausgezeichnet. Diese Auszeichnung würdigt das Engagement von FWF für AROBS, an der Spitze der Innovation im Bereich der Unternehmensautomatisierung zu stehen, auf der Grundlage der robotergestützten Prozessautomatisierung und unter Nutzung der Fähigkeiten der Agentic AI. Dies bestätigt auch die strategische Ausrichtung der AROBS Group, in Technologien zu investieren, die die Arbeitsweise von Unternehmen grundlegend verändern.

RENAULT GROUP: EMPLOYEE SHARE OWNERSHIP, A SUSTAINED COMMITMENT

RENAULT GROUP : L’ACTIONNARIAT SALARIÉ, UN ENGAGEMENT QUI S’ANCRE DURABLEMENT 

SHREWSBURY, United Kingdom, July 02, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, an AI-native decentralized infrastructure platform, today announced the start of its Final Bonus Phase, following the successful completion of all 15 presale stages and the achievement of a major milestone—$21.1 million raised from a global community of early contributors. This final round offers a fixed price of $0.007125 per LCAI token, providing one last opportunity for participants ahead of the mainnet launch scheduled for July 2025.

On 14 May 2025, the annual general meeting in Equinor ASA (OSE: EQNR, NYSE: EQNR) decided that the company's share capital shall be reduced by NOK 589,934,295 from NOK 6,981,953,075 to NOK 6,392,018,780, through cancellation and redemption of a total of 235,973,718 shares.

Generalforsamlingen i Equinor ASA (OSE: EQNR, NYSE: EQNR) vedtok den 14. mai 2025 at selskapets aksjekapital skal nedsettes med NOK 589.934.295 fra NOK 6.981.953.075 til NOK 6.392.018.780, ved sletting og innløsning av totalt 235.973.718 aksjer.

Vienintelio „Akropolis Group“ akcininko sprendimu naujai ketverių metų kadencijai perrinktas esamos sudėties „Akropolis Group“ audito komitetas.

OSE Immunotherapeutics provides an update on ongoing proceedings

OSE Immunotherapeutics met à jour l’information sur les procédures en cours